February 16, 2023 – OnDemand 

Biosimilars and specialty generics are the new hot ticket for the pharma industry. However, there may be a rocky road ahead. In this session, Jason Bogroff, Senior Principal, Blue Fin Group discussed:

• The coming specialty LOE wave
• Lessons learned from biosimilar and specialty generic launches
• Insights from a similar inflection point in 2010+
• How the specialty LOE wave may play out and the implications across payers, pharmacies, providers, and patients. 
• What you can do to prepare

Learn more about our strategic consulting solutions for effective commercialization and improved market access.

LEARN MORE

Jason Bogroff
Senior Principal, Blue Fin Group